Trial Profile
Single –arm, multicenter phase-II trial for catumaxomab and chemotherapy in patients with recurrent ovarian cancer to investigate the feasibility and clinical activity of initial intraperitoneal catumaxomab followed by chemotherapy regimes
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Catumaxomab (Primary) ; Doxorubicin; Gemcitabine; Paclitaxel; Topotecan
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- 17 Feb 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 20 Mar 2013 New source identified and integrated (ClinicalTrials.gov record: NCT01815528).
- 12 Jan 2013 New trial record